On the Record · Alkermes plc.
Alkermes plc. acquisitions, on the record
The businesses Alkermes plc. bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Athlone FacilityWord for word“In December 2023, we announced entry into a definitive agreement to sell our research and development and manufacturing facility in Athlone, Ireland (the “Athlone Facility”) where VUMERITY is manufactured, which transaction is expected to close in mid-2024.” 10-K for 2023 | agreed divestiture | December 2023 | — |
oncology business (Mural Oncology plc)Word for word“Distribution of Mural Oncology plc — — ( 293,760 ) — — — — ( 293,760 )” 10-K for 2023 | divestiture | — | — |
Athlone Facility and related business, sold to Novo NordiskWord for word“In May 2024, the Company completed the sale of its development and manufacturing facility in Athlone, Ireland (the “Athlone Facility”) and related business to Novo Nordisk (“Novo”) pursuant to an asset purchase agreement entered into in December 2023.” 10-K for 2024 | divestiture | May 2024 | — |
former oncology businessWord for word“In November 2023, we completed the separation of our former oncology business into a new, independent, publicly-traded company (the “Separation”), which is more fully described in Note 3, Discontinued Operations , in the “Notes to Consolidated Financial Statements” in this Annual Report.” 10-K for 2024 | divestiture | November 2023 | — |
Rodin Therapeutics, Inc.Word for word“Included within these loss and credit carryforwards are $14.1 million of U.S. federal NOL carryforwards and $5.8 million of state NOL 60 carryforwards, acquired as part of the acquisition of Rodin Therapeutics, Inc. (“Rodin”) in November 2019, each of which are subject to a $0.5 million annual limitation.” 10-K for 2024 | acquisition | November 2019 | — |
Elan Drug Technologies (“EDT”) from Elan Corporation, plcWord for word“The Company’s goodwill consists solely of goodwill created as a result of the Company’s acquisition of Elan Drug Technologies (“EDT”) from Elan Corporation, plc (such acquisition, the “Business Combination”) in September 2011 and has been assigned to one reporting unit.” 10-K for 2024 | acquisition | September 2011 | — |
Avadel Pharmaceuticals plcWord for word“On February 12, 2026, we successfully completed the Avadel Acquisition, adding both LUMRYZ to our portfolio of proprietary commercial products and a commercial organization with experience in narcolepsy.” 10-K for 2025 | acquisition | February 12, 2026 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses |
|---|---|---|
| 2019-12-31 | $8.9 million | — |
| 2024-12-31 | — | $97.9 million |
| 2025-12-31 | — | $1.7 million |
Deal filings since 2016
- 2026-08-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-02-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-02-12 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2025-11-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-10-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-09-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-12-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-11-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-11-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-08-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-07-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-04-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-12-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-11-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-03-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-11-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-10-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Alkermes plc.’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.